James Cardia, Ph.D.
Dr. James Cardia, is the Director of Business Development and Intellectual Property at RXi Pharmaceuticals. During his tenure at RXi, Dr. Cardia's group was responsible for the discovery and optimization of "self-delivering" rxRNAs (sd-rxRNAs®) as well as the development and characterization of RXI-109, a promising anti-fibrotic agent currently in clinical trials for the treatment of both dermal and retinal scarring. He has participated in multiple out-licensing, in-licensing and acquisition deals and has contributed to numerous publications and patent applications. Dr. Cardia has a Ph.D. in chemistry from Boston College and received postdoctoral training in the Department of Chemistry and Chemical Biology at Harvard University.